Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000
November 01, 2023 10:00 ET
|
Reset Pharmaceuticals Inc.
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental...
Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
January 05, 2023 08:00 ET
|
Reset Pharmaceuticals Inc.
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental...
Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors
November 02, 2022 08:00 ET
|
Reset Pharmaceuticals Inc.
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development and commercialization of novel...